Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics https://bit.ly/4h5jy0n
关于我们
The Antimicrobials Working Group (AWG) was founded in 2012 with the vision of utilizing collective power to improve the regulatory, investment, and commercial environment for emerging antimicrobials and diagnostics companies. Today, The Antimicrobials Working Group is comprised of thirteen emerging antimicrobial companies. In seven years of work, we have narrowed our focus onto enhanced reimbursement, expedited approval pathways, and sound stewardship measures. The emergence of multi-drug resistant bacteria presents a global public health crisis that demands new antimicrobials and diagnostic devices, yet the number of companies in the United States investing in research and development is dwindling due to lack of attractiveness for investment in the sector. AWG engages with key Congressional offices to help create policies and legislation that spur the development of life-saving antimicrobials and diagnostic devices through appropriate regulatory flexibility; fair and adequate reimbursement policies; and establishing a favorable investment climate to develop antimicrobial therapies and diagnostic devices.
- 网站
-
https://www.antimicrobialsworkinggroup.org/
Antimicrobials Working Group的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Washington,DC
- 类型
- 非营利机构
- 创立
- 2012
地点
-
主要
2200 Pennsylvania Ave NW
4th Floor East
US,DC,Washington,20037
Antimicrobials Working Group员工
动态
-
Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI https://bit.ly/4keHWPT
-
Iterum Therapeutics plc Reports Fourth Quarter and Full Year 2024 Financial Results https://bit.ly/416jyZm
-
Cormedix Inc. Announces Collaboration for DefenCath Promotion to the VA and Other Federal Facilities bit.ly/3PMsMDA
-
Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI) https://bit.ly/40681aB
-
SCYNEXIS, Inc. Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
-
Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) to Present at the Microcap Conference, January 28, 2025 - January 30, 2025 https://bit.ly/3OXijon
-
Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications
-
Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) sponsored and Participated in the Peggy Lillis Foundation Inaugural CDI Scientific Symposium and Presented Ibezapolstat Ph2b Clinical Data Update
-
Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) Reports Third Quarter 2024 Results and Provides Business Update https://bit.ly/4evlU7E